BCM
DMAQR

Bluefin Capital Management’s Deep Medicine Acquisition Corp. Rights DMAQR Stock Holding History

Bluefin Capital Management’s Portfolio DMAQR Stock Details DMAQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,975
Closed -$1.52K – 220
2022
Q4 		$749 Hold
14,975
– – ﹤0.01% 453
2022
Q3 		$1K Hold
14,975
– – ﹤0.01% 550
2022
Q2 		$2K Hold
14,975
– – ﹤0.01% 560
2022
Q1 		$3K Hold
14,975
– – ﹤0.01% 627
2021
Q4 		$5K Buy
+14,975
New +$4.74K ﹤0.01% 840

Other funds holding DMAQR

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Bluefin Capital Management's DMAQR Position: Q1 2023 in Review

Bluefin Capital Management sold out of Deep Medicine Acquisition Corp. Rights (DMAQR) in Q1 2023, closing a stake of 14,975 shares — an estimated $1.52K sold.

Bluefin Capital Management first reported a position in DMAQR in Q4 2021 and held it in 5 quarters. The position peaked at $5K in Q4 2021. 30 funds tracked by Wall St. Rank hold DMAQR as of Q1 2023.

  • Bluefin Capital Management reported no remaining Deep Medicine Acquisition Corp. Rights position as of Q1 2023 after selling out during the quarter.
  • Bluefin Capital Management sold 14,975 Deep Medicine Acquisition Corp. Rights shares in Q1 2023, an estimated $1.52K.
  • Bluefin Capital Management first reported a position in Deep Medicine Acquisition Corp. Rights in Q4 2021 and held it in 5 quarters.
  • Bluefin Capital Management's Deep Medicine Acquisition Corp. Rights position peaked at $5K in Q4 2021.
  • 30 funds tracked by Wall St. Rank held Deep Medicine Acquisition Corp. Rights as of Q1 2023.

Based on Bluefin Capital Management's 13F filing for Q1 2023, filed 15 May 2023.